Ascelia Pharma AB (OSTO:ACE)
kr 10.18 -0.35 (-3.5%) Market Cap: 343.65 Mil Enterprise Value: 322.86 Mil PE Ratio: 0 PB Ratio: 4.38 GF Score: 21/100

Q3 2023 Ascelia Pharma AB Earnings Call Transcript

Nov 09, 2023 / 01:30PM GMT
Release Date Price: kr2.88 (-3.52%)
Magnus Corfitzen Ascelia Pharma AB;CEO

Welcome, everyone, to the webcast for Ascelia Pharma's Q3 report here in 2023. The headline for this quarter is that the re-evaluation process is on track. And in this report, we'll give you an update on the business before opening up for questions.

We will be making certain forward-looking statements on this call, so please pay attention to this. Our quarterly call is structured so that we start with the Ascelia Pharma's highlighted recent key events that will be followed by a portfolio update before moving to financials. So I'm Magnus Corfitzen, CEO of Ascelia Pharma. And with me today, I have Julie Brogren, Deputy CEO; and Andreas Norlin, Chief Scientific Officer.

Ascelia Pharma is dedicated to improving the lives of people living with cancer by offering better treatment options. In particular, we focus on rare cancer conditions. Our business model is to identify, develop, and commercialize novel drugs that address unmet medical needs within orphan oncology.

We have two drugs in clinical development. Orviglance has completed

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot